December 16, 2016 / 7:47 PM / 10 months ago

BRIEF-Pfizer says FDA drops black box warning on anti-smoking drug Chantix

Dec 16 (Reuters) - Pfizer Inc

* FDA approves removal of boxed warning regarding serious neuropsychiatric events from Chantix (Varenicline) labeling

* Labeling revisions may further encourage smokers and healthcare providers to discuss smoking cessation treatment options

* updated warning in Chantix labeling notes that postmarketing reports of serious or clinically significant neuropsychiatric adverse events in patients treated with Chantix

* labeling revisions also include updates to corresponding warning and addition of clinical data on superior efficacy of chantix compared to bupropion or nicotine patch

* FDA approves removal of boxed warning regarding serious neuropsychiatric events from Chantix (Varenicline) labeling Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below